Validation of HPLC-UV methods for quantitatively determining landiolol and its major metabolite in human blood.
Landiolol is an ultra-short-acting beta(1)-adrenergic receptor blocking agent that is used for both perioperative and postoperative patients with tachycardia during general anesthesia. Validated HPLC-UV methods that quantitatively determine landiolol and its major metabolite (M-1) in human blood were reported for clinical research of landiolol. These analytes were recovered from the same blood sample using a multi-step extraction process and determined with two different HPLC conditions. These methods were validated over concentration ranges of 0.05 to 10 microg/ml for landiolol and 0.1 to 20 microg/ml for M-1 and were found to have acceptable accuracy, precision, linearity, and selectivity. These methods are useful to the characterize of blood pharmacokinetics of landiolol and M-1 for clinical research.
Hashimoto
Yoshitaka
Y
Pharmacokinetic Research Laboratories, Research Headquarters, Ono Pharmaceutical Co., Ltd., Tsukuba-shi, Ibaraki, Japan.
Nago
Sachiko
S
Tsunekawa
Masako
M
Shibakawa
Kimio
K
Miyata
Yasuyuki
Y
D001774:Blood Chemical Analysis; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D009025:Morpholines / Q000032:analysis* / Q000378:metabolism / Q000493:pharmacokinetics; D011786:Quality Control; D013056:Spectrophotometry, Ultraviolet / Q000379:methods*; D014508:Urea / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism / Q000493:pharmacokinetics
D009025:Morpholines; C077049:landiolol; D014508:Urea